# EDGAR Filing Document

**Accession Number:** 0001534133
**File Stem:** 0001193125-25-137807
**Filing Date:** 2025-6
**Character Count:** 6633
**Document Hash:** a9e1f6479e334359f8d25285cf29d42e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-137807.hdr.sgml**: 20250609

**ACCESSION NUMBER**: 0001193125-25-137807

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250609

**DATE AS OF CHANGE**: 20250609

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CalciMedica, Inc.
- **CENTRAL INDEX KEY:** 0001534133
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 452120079
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39538
- **FILM NUMBER:** 251034007

**BUSINESS ADDRESS:**
- **STREET 1:** 505 COAST BOULEVARD SOUTH
- **STREET 2:** SUITE 307
- **CITY:** LA JOLLA
- **STATE:** CA
- **ZIP:** 92037
- **BUSINESS PHONE:** 858-952-5500

**MAIL ADDRESS:**
- **STREET 1:** 505 COAST BOULEVARD SOUTH
- **STREET 2:** SUITE 307
- **CITY:** LA JOLLA
- **STATE:** CA
- **ZIP:** 92037

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CalciMedica, Inc. /DE/
- **DATE OF NAME CHANGE:** 20230322

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GRAYBUG VISION, INC.
- **DATE OF NAME CHANGE:** 20170717

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GRAYBUG, Inc.
- **DATE OF NAME CHANGE:** 20150303

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, D.C. 20549** 

**SCHEDULE 14A** 

**(Rule 14a-101)** 

**INFORMATION REQUIRED IN PROXY STATEMENT** 

**SCHEDULE 14A INFORMATION** 

**Proxy Statement Pursuant to Section 14(a) of the** 

**Securities Exchange Act of 1934** 

**(Amendment No.)** 

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))** 

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material Pursuant to §240.14a-12

## CALCIMEDICA, INC.
**(Name of Registrant as Specified In Its Charter)** 

**N/A** 

**(Name of Person(s) Filing Proxy Statement, if other than the Registrant)** 

Payment of Filing Fee (Check the appropriate box):

☒ No fee required.

☐ Fee paid previously with preliminary materials.

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

------

**SUPPLEMENT TO THE PROXY STATEMENT FOR THE ANNUAL MEETING OF STOCKHOLDERS** 

**TO BE HELD TUESDAY, JUNE 24, 2025** 

This proxy statement supplement (this "Supplement"), dated June 9, 2025, supplements the proxy statement filed with the Securities and Exchange Commission (the "Commission") on April 29, 2025 (the "Proxy Statement") relating to the proxies being solicited by the Board of Directors (the "Board") of CalciMedica, Inc., a Delaware corporation (the "Company" and "we" or "our"), in connection with the Company's 2025 Annual Meeting of Stockholders to be held on Tuesday, June 24, 2025 (the "Annual Meeting"). This Supplement should be read together with the Proxy Statement. Other than as set forth below, no changes have been made to the Proxy Statement.

The purpose of this Supplement is to provide information relating to the merger of the Company's independent registered public accounting firm.

On June 3, 2025, the Company was notified that Moss Adams LLP ("Moss Adams"), the Company's independent registered public accounting firm, merged with Baker Tilly US, LLP effective on June 3, 2025. The combined audit practices operate as Baker Tilly US, LLP ("Baker Tilly"). In connection with the notification of the merger, Moss Adams has resigned as the auditors of the Company and the Audit Committee of the Board approved the appointment of Baker Tilly, as the successor to Moss Adams, as the Company's independent registered public accounting firm.

The audit report of Moss Adams on the Company's consolidated financial statements for the year ended December 31, 2024 did not contain an adverse opinion or a disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope or accounting principles.

During the years ended December 31, 2024 and 2023, and the subsequent interim period through June 3, 2025, there were no (a) disagreements with Moss Adams on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which, if not resolved to Moss Adams' satisfaction, would have caused it to make reference to the subject matter of the disagreement in connection with its reports on the Company's financial statements, or (b) reportable events requiring disclosure pursuant to Item 304(a)(1)(v) of Regulation S-K.

During the years ended December 31, 2024 and 2023, and the subsequent interim period through June 3, 2025, neither the Company, nor anyone on its behalf, consulted with Baker Tilly regarding: (i) either the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company's financial statements; or (ii) any matter that was either the subject of a "disagreement," as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to that item, or a "reportable event," as described in Item 304(a)(1)(v) of Regulation S-K.

The Company provided Moss Adams with a copy of this Supplement prior to its filing with the Commission and requested that Moss Adams furnish the Company with a letter addressed to the Commission stating whether it agrees with the above statements and, if it does not agree, the respects in which it does not agree. A copy of Moss Adams' letter to the Commission, dated June 6, 2025, is filed as Exhibit 16.1 to the Current Report on Form 8-K filed by the Company on June 6, 2025.

With respect to Proposal No. 2 included in the Proxy Statement, to ratify the appointment of Moss Adams LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025, we will consider an affirmative vote "For" Proposal No. 2 as a vote "For" ratification of Baker Tilly as the successor accounting firm following the merger and a vote "Against" Proposal No. 2 as a vote "Against" ratification of Baker Tilly as the successor accounting firm following the merger. Abstentions and broker non-votes will have no effect.

Proxy voting instructions already returned by stockholders will remain valid and will be voted at the Annual Meeting unless revoked. Important information regarding how to vote your shares and how to change votes already cast is available in the Proxy Statement.